For research use only. Not for therapeutic Use.
Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor.
Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study[1].
| Catalog Number | I001809 |
| CAS Number | 1476777-06-6 |
| Synonyms | 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxylic acid |
| Molecular Formula | C19H19N3O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H19N3O2/c23-19(24)17-5-1-3-15-12-22(21-18(15)17)16-8-6-13(7-9-16)14-4-2-10-20-11-14/h1,3,5-9,12,14,20H,2,4,10-11H2,(H,23,24)/t14-/m1/s1 |
| InChIKey | HDQHGRLURKGIFL-CQSZACIVSA-N |
| SMILES | C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)O |
| Reference | [1]. van Andel L, et al. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 19;1040:14-21 |
